Samantha Semenkow, an analyst from Citi, maintained the Hold rating on BioAge Labs, Inc. (BIOA – Research Report). The associated price target was lowered to $5.00.
Samantha Semenkow’s rating is based on the current developmental progress and market potential of BioAge Labs, Inc. The company is advancing its BGE-102 program, with an IND filing expected in 2025 and initial Phase 1 data anticipated in the second half of 2025. Additionally, BioAge is working on preclinical development of apelin receptor agonists. Despite these promising developments, the stock is expected to remain relatively stable over the next year due to a lack of significant catalysts.
Samantha Semenkow has also noted that while there are potential opportunities in large markets such as obesity and neuroinflammatory conditions, the current risk level is considered high. The target price has been adjusted to $5, reflecting a cautious outlook. However, future developments, including third-party NLRP3 readouts and potential collaborations, could renew investor interest in the stock.
According to TipRanks, Semenkow is an analyst with an average return of -19.2% and a 27.38% success rate. Semenkow covers the Healthcare sector, focusing on stocks such as BioAge Labs, Inc., Catalyst Pharma, and Voyager Therapeutics.